Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide

Oncolytic herpes simplex virus (oHSV) mutants are under development as anticancer therapeutics. One such vector, rRp450, is ICP6-deleted and expresses a prodrug enzyme for cyclophosphamide (CPA) (rat CYP2B1). Little is known about rRp450’s toxicity profile, especially in combination with CPA. We tes...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Currier, Mark A, Gillespie, Rebecca A, Sawtell, Nancy M, Mahller, Yonatan Y, Stroup, Greg, Collins, Margaret H, Kambara, Hirokazu, Chiocca, E Antonio, Cripe, Timothy P
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860295/
https://ncbi.nlm.nih.gov/pubmed/18388918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2008.49
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky